trending Market Intelligence /marketintelligence/en/news-insights/trending/IxZPrWhBvoOtgt3UKk666g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Foamix files for US FDA approval of rosacea treatment

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Foamix files for US FDA approval of rosacea treatment

Foamix Pharmaceuticals Ltd. has submitted a new drug application to the U.S. Food and Drug Administration seeking approval for its experimental skin condition drug FMX103.

If approved, FMX103 would treat moderate-to-severe papulopustular rosacea in adults, a condition characterized by redness and visible blood vessels in the face. Rosacea, often mistaken for acne, can also cause small, red, pus-filled bumps to form.

The Israeli dermatology company's application is based on positive data from two late-stage studies, Foamix said in an Aug. 5 press release.

According to Foamix, approximately 16 million individuals in the U.S. have rosacea, and about 85% experience sensitivity to the available treatment options.